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Introduction
Pancreatic cancer has a very poor prognosis. Currently, 
surgical resection is the only possible treatment to obtain 
long- term survival [1]. The recent CONKO- 001 rand-
omized clinical trial has demonstrated an additional benefit 
of adjuvant chemotherapy on disease- free and overall 
survival for pancreatic cancer [2]. These results were 
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Abstract
Adjuvant chemotherapy after pancreatoduodenectomy for pancreatic cancer is 
currently considered standard of care. In this nationwide study, we investigated 
which characteristics determine the likelihood of receiving adjuvant chemotherapy 
and its effect on overall survival. The data were obtained from the Netherlands 
Cancer Registry. All patients alive 90 days after pancreatoduodenectomy for 
M0- pancreatic cancer between 2008 and 2013 in the Netherlands were included 
in this study. The likelihood to receive adjuvant chemotherapy was analyzed 
by multilevel logistic regression analysis and differences in time- to- first- 
chemotherapy were tested for significance by Mann–Whitney U test. Overall 
survival was assessed by Kaplan–Meier method and Cox regression analysis. Of 
the 1195 patients undergoing a pancreatoduodenectomy for pancreatic cancer, 
642 (54%) patients received adjuvant chemotherapy. Proportions differed sig-
nificantly between the 19 pancreatic centers, ranging from 26% to 74% 
(P < 0.001). Median time- to- first- chemotherapy was 6.7 weeks and did not 
differ between centers. Patients with a higher tumor stage, younger age, and 
diagnosed more recently were more likely to receive adjuvant treatment. The 
5- year overall survival was significantly prolonged in patients treated with ad-
juvant chemotherapy—23% versus 17%, log- rank = 0.01. In Cox regression 
analysis, treatment with adjuvant chemotherapy significantly prolonged survival 
compared with treatment without adjuvant chemotherapy. The finding that el-
derly patients and patients with a low tumor stage are less likely to undergo 
treatment needs further attention, especially since adjuvant treatment is known 
to prolong survival in most of these patients.
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obtained in all age groups, for both sexes and independ-
ent of tumor stage [2]. Given these results, adjuvant 
chemotherapy is now considered standard of care in most 
countries including the Netherlands, where adjuvant 
chemotherapy (Gemcitabine) has been recommended by 
the Dutch society of Medical Oncology (NVMO) since 
2008 [3].
In the Netherlands, surgery for pancreatic cancer is 
only performed in centers performing at least 20 pan-
creatoduodenectomies (PD) annually. This centralization 
significantly improved outcomes of pancreatic surgery in 
terms of postoperative morbidity and mortality [4, 5]. In 
contrast, systemic treatment of pancreatic cancer patients, 
including adjuvant chemotherapy in operated patients is 
given in almost all hospitals in the Netherlands. Previous 
studies have shown that a considerable amount of patients 
do not receive adjuvant chemotherapy after recovery from 
a pancreatoduodenectomy [6–8]. It is currently unknown 
which factors determine the likelihood for receiving adju-
vant chemotherapy. Therefore, this nationwide study 
investigated the variation between pancreatic centers in 
adjuvant treatment and which characteristics determine 
the likelihood of receiving adjuvant chemotherapy in the 
Netherlands. By doing so, correctable reasons for underu-
tilization of adjuvant chemotherapy may be identified, 
thereby raising the possibility to further improve the treat-
ment of pancreatic cancer patients.
Patients and Methods
Data collection
Data were obtained from the nationwide Netherlands 
Cancer Registry (NCR). This registry contains data of all 
newly diagnosed cancer patients in the Netherlands 
(approximately 16.8 million inhabitants in 2013), which 
is routinely extracted from the medical records in all 
hospitals and registered by specially trained, independent 
administrators. The NCR contains patient, tumor, and 
treatment characteristics. The extent of disease was defined 
by pathological findings, and was staged using the TNM 
classification or pathologic extent of disease (pEoD). pEoD 
classifications were converted to TNM classification [9, 
10]. In pEoD classification, tumor involvement of the 
truncus coeliacus or arteria mesenterica superior (AMS) 
is not specified. Therefore, no differentiation between TNM 
stage II or III could be made, and these patients were 
categorized as TNM II/III.
Patient selection
All nonmetastatic (M0) patients diagnosed with adenocarci-
noma of the pancreas (ICD C25) [11] between 1 January 
2008 and 31 December 2013 in the Netherlands and  surgically 
treated by PD in a pancreatic center were included in this 
study. Patients diagnosed with carcinoma- in- situ (Tis), neu-
roendocrine tumors, patients with missing data on tumor 
stage, and patients deceased within 90 days after surgical 
treatment were excluded from further analysis (n = 218). 
This landmark at 90 days, postoperative, was chosen to 
minimize the possible effect of postoperative complications 
on the administration of adjuvant chemotherapy and to deal 
with immortal time bias of patients receiving chemotherapy. 
Adjuvant chemotherapy was defined as any chemotherapeuti-
cal treatment starting within 16 weeks after surgery.
Pancreatic center
In the Netherlands, a minimum of 20 PDs per year is 
currently required to be considered as a pancreatic center. 
This resulted in 19 pancreatic centers in the Netherlands 
in 2013, including eight university hospitals.
Statistical analysis
Differences in patient- and tumor characteristics between 
patients who underwent adjuvant chemotherapy and 
patients who did not were compared with chi- square tests. 
To analyze the hierarchically structured data of patients 
nested within pancreatic centers, a multilevel logistic regres-
sion analysis was used. Multilevel regression analyses pro-
vide more accurate estimates when dealing with 
hierarchically structured data than traditional regression 
analyses as they account for dependency of patients within 
pancreatic centers [12, 13]. The outcome variable was 
adjuvant chemotherapy (0, no; 1, yes). Patient- and tumor- 
related variables (sex, age, TNM stage, year of diagnosis) 
were added to the multivariable multilevel model. The 
effect of a variable on the likelihood of adjuvant chemo-
therapy was expressed as an odds ratio (OR) with 95% 
Confidence Interval (CI).
Each patient’s adjusted chance to undergo adjuvant 
chemotherapy was given by the following formula: 
P = eL⁄(1 + eL), where L is the calculated value from 
the logistic regression for that particular patient. The mean 
adjusted probability to undergo adjuvant chemotherapy 
for each pancreatic center was defined as the mean adjusted 
surgical probability of the patients within that pancreatic 
center. This resulted in a range of probabilities to undergo 
adjuvant chemotherapy adjusted for differences in patient-
 and tumor characteristics between pancreatic centers. The 
variation in adjuvant chemotherapy probabilities between 
pancreatic centers was tested for statistical significance by 
means of ANOVA with Bonferroni correction.
The differences in comparisons made for the time 
period between surgery and start of adjuvant 
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chemotherapy, defined as time to adjuvant chemotherapy 
in weeks, were tested for significance using the nonpara-
metric Mann–Whitney U test.
Conditional survival
Data retrieved from the Municipal Personal Records Database 
(BRP) were used to calculate survival. In the BRP, all deaths 
or emigrations of Dutch inhabitants are registered. Survival 
time was defined as time from diagnosis to death, or until 
1 January 2015 for patients who were still alive. The Kaplan–
Meier method was used to determine 5- year survival. The 
effect of the time to adjuvant chemotherapy on the overall 
survival was assessed by log- rank test. Multivariable Cox 
regression analysis was undertaken to investigate the prog-
nostic impact of adjuvant chemotherapy on overall survival, 
after adjustment for patient characteristics. Results from 
survival analyses using Cox regression analysis were reported 
as hazard ratios (HR) with 95% CI.
All analyses were performed using Statistical Analysis 
Software (SAS) version 9.4, North Carolina, USA and a 
P < 0.05 was considered statistically significant.
Results
Patients
Between 2008 and 2013, 5846 patients were diagnosed 
with M0- pancreatic cancer in the Netherlands of whom 
1413 (24%) underwent PD in a pancreatic center. In total, 
218 patients were excluded. The main reasons for 
exclusion were diagnosis of a neuroendocrine tumor 
(n = 78) and death within 90 days after surgery (n = 84). 
The remaining 1195 patients were included in this study. 
Adjuvant chemotherapy was administered to 642 (54%) 
of these patients, either in the pancreatic center where 
the surgery was performed (56%) or in the referring hos-
pital (44%). Baseline characteristics differed between 
patients treated with and without adjuvant chemotherapy, 
with patients receiving chemotherapy being younger 
(median 64 vs. 70 years, respectively, P < 0.001) and 
being diagnosed with a higher TNM tumor stage (Table 1).
Center of surgery
The observed proportion of patients receiving adjuvant 
chemotherapy differed significantly between the 19 pan-
creatic centers in the Netherlands and ranged from 26% 
to 74%, P < 0.001 (Fig. 1). Multilevel logistic regression 
confirmed the effect of the pancreatic center on the prob-
ability to undergo adjuvant chemotherapy. The case- mix 
adjusted probability for adjuvant chemotherapy treatment 
ranged between 35% and 68% according to the pancreatic 
centers (Fig. 2; P < 0.001).
No significant difference was found in the observed 
treatment percentages between university pancreatic centers 
and nonuniversity pancreatic centers (55% vs. 52%, 
P = 0.245).
Variables influencing the likelihood of receiving adjuvant 
chemotherapy are presented in Table 2. Multilevel logistic 
regression model showed that an increased likelihood of 
adjuvant treatment was observed in patients with a TNM 
Table 1. Baseline characteristics of M0- pancreatic cancer patients treated by pancreatoduodenectomy between 2008 and 2013 in the Netherlands.
Variables n = 1195
Adjuvant chemotherapy No adjuvant chemotherapy
P- valuen = 642 (54%) n = 553 (46%)
Sex
Male 615 (51%) 329 (51%) 286 (52%) 0.871
Female 580 (49%) 313 (49%) 267 (48%)
Age
<60 years 285 (24%) 201 (31%) 84 (15%) <0.001
60–75 years 715 (60%) 409 (64%) 306 (55%)
≥75 years 195 (16%) 32 (5%) 163 (30%)
TNM stage
I 157 (13%) 54 (8%) 103 (19%) <0.001
II/III 1,038 (87%) 588 (92%) 450 (81%)
Year of diagnosis
2008 129 (11%) 42 (7%) 87 (16%) <0.001
2009 162 (14%) 87 (13%) 75 (13%)
2010 162 (14%) 84 (13%) 78 (14%)
2011 188 (15%) 98 (15%) 90 (16%)
2012 278 (23%) 164 (26%) 114 (21%)
2013 276 (23%) 167 (26%) 109 (20%)
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tumor stage II or III compared to TNM stage I (respec-
tively, 57% vs. 34%, OR 2.71, 95% CI: 1.77–4.15). 
Furthermore, patients older than 60 years were less likely 
to undergo adjuvant chemotherapy (70% <60 years vs. 
57% 60–75 years, OR 0.48, 95% CI: 0.34–0.67). Patients 
older than 75 years were the least likely to receive chemo-
therapy (16%, OR 0.06, 95% CI: 0.04–0.10).
Over time, the use of adjuvant chemotherapy increased 
from 33% in 2008 to 61% in 2013. Patients diagnosed 
in the year 2013 were more likely to undergo adjuvant 
treatment compared to patients diagnosed in 2008 (OR 
4.63, 95% CI: 2.73–7.87).
Time to adjuvant chemotherapy
In 400 (62%) patients, adjuvant chemotherapy was initi-
ated within 8 weeks after PD, in 134 (21%) patients, 
between 8 and 12 weeks postoperatively, and in 23 (4%) 
patients, treatment was started more than 12 weeks after 
PD. In 85 (13%) patients, information on time to adjuvant 
chemotherapy was missing. Median time to adjuvant 
chemotherapy was 6.6 weeks (Interquartile range [IQR]: 
2.9). The time to adjuvant chemotherapy did not signifi-
cantly differ between patients resected in university centers 
versus nonuniversity centers, P = 0.803 (respectively, 
median 6.7, IQR: 2.7 vs. median: 6.4, IQR: 3.3). 
Furthermore, no difference in time to adjuvant chemo-
therapy was found for patients treated in a pancreatic 
center versus patients referred to a nonpancreatic center 
for receiving adjuvant chemotherapy, P = 0.194 (respec-
tively, median: 6.3, IQR: 2.9 vs. median: 7.0, IQR: 3.4).
Figure 1. Observed percentage of adjuvant chemotherapy treatment in 
pancreatic cancer patients undergoing pancreatoduodenectomy in 
pancreatic centers between 2008 and 2013 in the Netherlands.
Figure 2. Multilevel case- mix adjusted probability for adjuvant 
chemotherapy treatment for pancreatic centers in the Netherlands 
between 2008 and 2013.
Table 2. Multilevel logistic regression analyses for the likelihood of 
 adjuvant chemotherapy treatment among M0- pancreatic cancer 
 patients diagnosed between 2008 and 2013 and surgically treated by 




N = 642 (54%) Odds ratio 95% CI
Sex
Male 329 (54%) 1
Female 313 (54%) 1.06 0.81–1.40
Age
<60 years 201 (71%) 1
60–75 years 409 (57%) 0.48* 0.34–0.67
≥75 years 32 (16%) 0.06* 0.04–0.10
TNM stage
I 54 (34%) 1
II/III 588 (57%) 2.71* 1.77–4.15
Year of diagnosis
2008 42 (33%) 1
2009 87 (54%) 2.83* 1.61–4.98
2010 84 (52%) 2.85* 1.61–5.05
2011 98 (52%) 3.42* 1.96–5.99
2012 164 (59%) 4.39* 2.59–7.46
2013 167 (61%) 4.63* 2.73–7.87
Corrected for pancreatic center, intercept 0.275, SE 0.127.
*Significantly different
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Conditional survival
Kaplan–Meier analysis (Fig. 3) revealed a significant dif-
ference in 5- year overall survival rates based on whether 
patients were treated by adjuvant chemotherapy—23% 
versus 17% if not treated by adjuvant chemotherapy (Log- 
rank < 0.001). Patients treated with adjuvant chemotherapy 
had a 5- year survival rate of 22% if time to adjuvant 
chemotherapy was ≤6 weeks versus 21% for time to 
adjuvant chemotherapy >6 weeks. In Cox regression analy-
ses (Table 3), adjuvant chemotherapy treatment was a 
significant predictor of prolonged survival for both adjuvant 
chemotherapy within 6 weeks as well as for adjuvant 
chemotherapy after 6 weeks compared with no adjuvant 
chemotherapy (HR: 0.68, 95% CI: 0.56–0.82 vs. HR: 0.79, 
95% CI: 0.66–0.95). A tumor stage TNM II/III was a 
significant variable for shortened survival (HR: 1.97 95% 
CI: 1.58–2.47).
Discussion
The current population- based study revealed that 54% of 
the pancreatic cancer patients received adjuvant chemo-
therapy following PD. Elderly patients were less likely 
to undergo adjuvant chemotherapy. Interestingly, the 
 likelihood of receiving adjuvant chemotherapy treatment 
varied significantly between pancreatic centers. Survival 
analyses showed that the addition of adjuvant chemo-
therapy was associated with a prolonged survival. This 
was seen in patients receiving adjuvant chemotherapy 
within 6 weeks postoperatively but also in patients receiv-
ing chemotherapy more than 6 weeks after PD.
Our findings on overall survival are in line with a recent 
RCT (randomized clinical trial) and a previous population- 
based study in the USA showing a positive influence of 
adjuvant chemotherapy on overall survival [2, 6]. This 
again stresses the beneficial effect of treating patients with 
adjuvant chemotherapy, if possible. A recent study in the 
Netherlands showed limited compliance to quality indica-
tors in pancreatic cancer care based on the Dutch guideline. 
The administration of adjuvant chemotherapy increased 
from 45% of patients in 2010 to 54% in 2012 [14]. 
Nevertheless, the proportion of patients treated by adjuvant 
chemotherapy in this study is comparable to percentages 
described in literature. Mayo et al. [6] reported adjuvant 
treatment in 51% of patients undergoing any type of sur-
gery for pancreatic adenocarcinoma in Medicare beneficiar-
ies in the USA. A multicenter study in Japan demonstrated 
that 66% of the pancreatic cancer patients received adjuvant 
chemotherapy [15]. Finally, a study by Aloia et al. [7] 
Figure 3. Kaplan–Meier, 5- year overall survival adjuvant chemotherapy versus no adjuvant chemotherapy after pancreatoduodenectomy in pancreatic 
cancer patients in the Netherlands between 2008 and 2013.
Table 3. Cox regression analyses among M0- pancreatic cancer patients 
diagnosed between 2008 and 2013 in the Netherlands and surgically 
treated by pancreatoduodenectomy.






60–75 years 1.06 0.90–1.26













Yes (started ≤6 weeks postoperative) 0.68* 0.56–0.82
Yes (started >6 weeks postoperative) 0.79* 0.67–0.95
Yes (date of start missing) 0.71* 0.54–0.93
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showed the highest percentage: 74% of patients received 
adjuvant therapy after PD. However, in spite of this high 
percentage, the authors suggested that at least 90% of 
patients with localized pancreatic adenocarcinoma and good 
pretreatment performance status would have been candi-
dates for postoperative adjuvant therapy.
A similar limited use of adjuvant chemotherapy has 
been shown in other tumors. For instance, only 60% 
patients with colon cancer and lymph node metastases 
received adjuvant chemotherapy in the Netherlands [16].
Remarkably, the proportion of patients receiving adjuvant 
chemotherapy varied significantly between pancreatic cent-
ers in this study. This finding was not in line with expec-
tations, as all pancreatic centers are supposed to have 
expert knowledge in the treatment of pancreatic cancer 
and to adhere to the national guidelines. The differences 
in the probability to receive adjuvant chemotherapy 
remained present after adjustment for available case- mix 
variables; sex, age, TNM stage, year of diagnosis. There 
may be various explanations for this phenomenon. First 
of all, the multidisciplinary tumor boards (MDTB) in the 
19 pancreatic centers may have various attitudes toward 
the guideline recommendations, resulting in a different 
tendency to advice adjuvant chemotherapy. Since a sig-
nificant proportion of the patients (44%) were not treated 
in the pancreatic center but in the referring hospital, medi-
cal oncologists from referring hospitals may choose to react 
differently on the advice of the MDTB. Furthermore, it 
should be acknowledged that in some cases, patients choose 
to not undergo adjuvant chemotherapy. This decision- 
making process will be the subject of further research.
In this study, age was an important variable in selecting 
patients with older patients being less likely to receive 
adjuvant chemotherapy. Previous retrospective studies have 
reported also an effect of age on the selection of patients 
for adjuvant chemotherapy [8, 17]. However, it was shown 
in the CONKO- 001 trial that the beneficial effects of 
adjuvant chemotherapy were obtained regardless of age 
[2]. Also in the cohort study by Nagrial et al., [17] it 
was demonstrated that adjuvant chemotherapy in elderly 
patients was associated with an improved survival to at 
least a similar degree as for younger patients. Furthermore, 
it is known that PDs can be safely performed in elderly 
patients with good postoperative outcomes [18, 19]. 
Therefore, physicians may be too reluctant in prescribing 
adjuvant chemotherapy to elderly patients.
Patients diagnosed with a tumor stage TNM II or III, 
were more likely to receive adjuvant chemotherapy treatment 
as compared to patients with stage I disease. Given the worse 
prognosis in stage TNM II or III patients, especially in the 
case of lymph node metastases, treating physicians may be 
more willing to administer adjuvant chemotherapy in these 
patients. However, as was shown by Oettle and colleagues, 
the beneficial results of adjuvant chemotherapy were not 
only achieved in high- staged tumors but also in low- staged 
tumors [2]. Therefore, adjuvant chemotherapy treatment of 
patients with stage I disease needs further attention.
This study had some limitations. Although the NCR 
registry is a reliable and complete database, data like 
resection status (R0/R1), postoperative complications, 
comorbidities, and performance status are lacking. These 
factors may have influenced the likelihood of receiving 
adjuvant chemotherapy treatment. Insurance status is not 
likely to affect the likelihood for adjuvant chemotherapy 
because of the equally accessible health care system in 
the Netherlands. Data on type of chemotherapy and com-
pletion rates in patients undergoing adjuvant chemotherapy 
were not registered. In our study, an effort to minimize 
the possible effect of postoperative complications on the 
administration of adjuvant chemotherapy was undertaken 
by excluding patients deceased within 90 days. A correla-
tion between severe complications and omission of adjuvant 
treatment was reported earlier by Wu et al., [8]. 
Furthermore, they described a decreased likelihood for 
adjuvant chemotherapy if the length of postoperative stay 
exceeded 9 days [8]. The results of that study showed 
that withdrawal of adjuvant chemotherapy in some cases 
could be explained by a prolonged postoperative recovery 
were early initiation of adjuvant chemotherapy could not 
be achieved caused by postoperative complications [6–8]. 
However, recently, Valle et al. [20] reported that survival 
following start of adjuvant chemotherapy treatment within 
8- 12 weeks postoperatively did not differ from initiation 
within 8 weeks postoperatively. Completion of the full 
course of the treatment was a more important factor 
determining outcomes. Likelihood of completion of the 
full course was maximized by an adequate postoperative 
recovery. Consequently, an inability of administering adju-
vant chemotherapy prior to 8 weeks postoperatively does 
not eliminate the beneficial effect of chemotherapy, as 
was confirmed by our study [20]. The observed median 
time of 6.6 weeks between PD and initiation of adjuvant 
chemotherapy, however, suggests that there might have 
been a nihilistic approach to a late start of adjuvant 
chemotherapy. In summary, there is an underuse of adju-
vant chemotherapy for pancreatic cancer in the 
Netherlands. Even in the last year of this study, only 
61% of the patients received adjuvant treatment. Elderly 
patients were less likely to undergo adjuvant chemotherapy, 
despite the beneficial effect of such treatment also in this 
age group. Interestingly, the likelihood of receiving adju-
vant chemotherapy treatment varied significantly between 
pancreatic centers, a finding that may not be explained 
by case- mix alone. This finding clearly needs further atten-
tion and more research, especially since in this study, 
treatment with adjuvant chemotherapy resulted in a 
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 significantly prolonged overall survival. The Dutch 
Pancreatic Cancer Project (PACAP) including prospective 
audit, are used for improvements in the use of adjuvant 
chemotherapy and other relevant factors in survival for 
pancreatic cancer care in the Netherlands.
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